// App-Quantinova.ai

BSH2020‐PO‐150 : Breakthrough hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: results of a 52‐week extension from two phase 3 studies

Researchers

Presenter

  • A. Hill

Principal Investigators

  • T. Munir

  • C. Piatek

  • R. Peffault de la Tour

  • L. Wong Lee Lee

  • R. Wells

  • R. Brodsky

  • J. S. Kim

  • J. Nishimura

  • P. Kuriakose

  • R. Pavani

  • P. Liu

  • S. Ortiz

  • H. Schrezenmeier

  • J. W. Lee

  • A. Kulasekararaj

Medical Centers

  • Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds,

  • Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA

  • Bone Marrow Transplantation Unit, Saint Louis Hospital, Assistance Publique–Hôpitaux de Paris

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint Louis Hospital and University Paris Diderot, Paris, France

  • Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu,Sabah,Malasia

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Yonsei University College of Medicine, Seoul, Korea

  • Kinki University, Osaka, Japan

  • Henry Ford Health System, Detroit, MI

  • Alexion Pharmaceuticals, Inc., Boston, MA, USA

  • Institute of Transfusion Medicine, University of Ulm, Germany ,

  • Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Service Baden-Wurttemberg, University Hospital Ulm, Ulm, Germany

  • Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea,

  • Department of Haematological Medicine,King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility,London,United Kingdom

Locations

  • United Kingdom

  • United States

  • France

  • Malaysia

  • Canada

  • Japan

  • Germany

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Male Sexual Dysfunction

  • Venous thrombosis

  • Dyspnea

  • Anemia

Biomarkers

  • Carbonic anhydrase II

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

  • ALXN-1210

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02946463

  • NCT03056040

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved